Loading
Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.
Previous close
$6.13
+$0.17 · +2.85%
Pre-market
$6.22
+$0.09 · +1.47%
Oct 8, 7:00 AM ET
Regular session · ET · Market data may be delayed.
Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.
Day range
Current $6.13
52-week range
Current $6.13
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
76
Undervalued
Sentiment
48
Mixed
Risk
55
Elevated Risk
Momentum
47
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.
Day range
Current $6.13
52-week range
Current $6.13
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 6.44M USD | 29.62M USD | 46.8M USD | 140.73M USD | 235.31M USD |
| Cost of goods sold | 556K USD | 15.56M USD | 3.96M USD | 20.28M USD | 449.19M USD |
| Gross profit | 5.88M USD | 14.06M USD | 42.84M USD | 120.45M USD | −213.88M USD |
| Research and development | 23.52M USD | 95.69M USD | 266.47M USD | 296.79M USD | 387.04M USD |
| Selling, general, and administrative | 27.71M USD | 49.33M USD | 86.48M USD | 124.69M USD | — |
| Operating expenses | 51.78M USD | 164.48M USD | 365.56M USD | 421.48M USD | 74.65M USD |
| Interest income | 2.94M USD | 5.3M USD | 7.59M USD | 7.6M USD | — |
| Interest expense | 8.76M USD | 8.25M USD | 8.1M USD | 1.44M USD | 1.08M USD |
| Depreciation and amortization | 748K USD | 2.69M USD | 9.93M USD | 10.6M USD | 14.81M USD |
| Operating income | −45.9M USD | −150.42M USD | −322.72M USD | −301.03M USD | −288.53M USD |
| Net income | 183.45M USD | −47.58M USD | −284.23M USD | −293.65M USD | −290.02M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$28.00
356.77% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jun 17, 2025 | 1:25 | — | — |
Effective Jun 17, 2025
1:25
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
